DiaSorin faces a squeeze as hospitals and labs push harder on prices and more testing shifts away from big lab machines, putting its long-standing products under pressure. See why some analysts think even with cost cuts and new specialty tests, the business may struggle to meet today’s expectations.Read more
Key Takeaways Expansion in North America and emerging markets, along with new specialty diagnostics, supports sustained revenue growth and improved profitability from widening healthcare demand. Manufacturing optimization and innovative test development drive operational efficiencies, premium pricing, and strengthened margins amid ongoing industry price pressures.Read more
Key Takeaways Expansion in the U.S. hospital market and innovative diagnostics could drive revenue and earnings growth well above current analyst expectations. Manufacturing efficiencies and investments in automation and connectivity may fuel margin expansion and strengthen the company's advantage in both institutional and near-patient settings.Read more
DiaSorin S.p.A. engages in research and development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, North America, and internationally. It provides various immunodiagnostic in the areas, including infectious diseases, gastrointestinal diseases, hepatitis and retroviruses, endocrinology, metabolic disorders, tumor markers, and oncology under LIAISON XL and LIAISON XS name. The company also offers Simplexa, a congenital CMV direct kit, which detects cytomegalovirus DNA in saliva swab and urine specimens. In addition, it offers LIAISON PLEX Respiratory Flex Assay and the LIAISON PLEX Yeast Blood Culture Assay. Further, the company offers xMAP technology platform, including in vitro diagnostics. The company was founded in 1968 and is headquartered in Saluggia, Italy.
